Moderna closes $3.0B 0% convertible notes due 2032; conversion at $210.58

Moderna, Inc.

$3.0B aggregate 0.00% convertible senior notes due 2032; conversion price $210.58 (47.5% premium to $142.77).
Net proceeds ~$2,957.3M; $328.8M used for capped call transactions, rest for oncology growth and debt repayment.
Capped calls cap price $392.62/share (175% premium), reducing dilution on conversion.
Notes convertible into up to 14,246,100 shares initially; max 21,012,600 in limited cases.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.